Biomea Fusion Touts Additional Preclinical Data For Blood Cancer Candidate

Biomea Fusion Inc BMEA announced the presentation of two posters at the 19th International Myeloma Society (IMS) Annual Meeting.
The first presentation covered preclinical data from BMF-219 in high-grade B-cell lymphoma and multiple myeloma.
BMF-219 exhibits multi-fold higher potency and complete growth inhibition in these preclinical models than clinical reversible menin inhibitors, demonstrating its unique antitumor potential in TP53, KRAS, and NRAS mutated cancers.
Related: Biomea Fusion Shares BMF-219 Preclinical Data At AACR 2022 Meeting.
The second presentation detailed a Phase 1 study of BMF-219 in patients with relapsed/refractory acute leukemia, diffuse large B-cell lymphoma, and multiple myeloma.
Doses of BMF-219 will be escalated in single-subject cohorts independently for each indication until one subject experiences a ≥ Grade 2 related adverse event or dose-limiting toxicity (DLT).
The primary objective is to determine independently for each cohort/indication the optimal biological dose/ recommended Phase 2 dose (RP2D) of BMF-219 oral monotherapy.
Key secondary objectives include further evaluation of safety and tolerability, antitumor activity based on best overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and time to progression.
Enrollment in COVALENT-101 commenced in January 2022.
Price Action: BMEA shares are down 1.28% at $12.35 on the last check Friday.